Результаты поиска

Glucagon-Like Peptide-1 Receptor Agonist Use in Obese Patients Is Associated With Decreased Risk of Revision and Retears After Arthroscopic Rotator Cuff Repair.

PURPOSE: To evaluate the impact of preoperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) use on medical complications, emergency department use, and orthopaedic complications in obese patients undergoing arthroscopic rotator cuff repair. METHODS: Obese patients (defined by relevant ICD-10 codes and confirmed by body mass index measurements) undergoing primary arthroscopic rotator cuff repair before June 2023 with at least 2-year follow-up were found in the TriNetX database and stratified according to GLP-1 RA use before surgery. Patients prescribed GLP-1 RAs were propensity-matched

GLP-1 Receptor Agonists as Pharmacologic Treatment for Obesity After Spinal Cord Injury: Clinical Considerations.

Individuals with spinal cord injury (SCI) face a disproportionate burden of obesity and cardiometabolic disease, however, evidence to guide pharmacologic treatment is minimal. Mainstay diet and exercise recommendations often yield modest, unsustainable results for those with SCI. In the general population, glucagon-like peptide-1 receptor agonists and dual agonists (GLP-1s) have emerged as potent therapies for obesity and related cardiometabolic disorders. Initially developed for type 2 diabetes mellitus, GLP-1s improve glycemic control, promote substantial weight loss, and reduce other cardio

Adherence and Persistence to Injectable versus Oral GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus: A Comparative Systematic Review and Analysis.

BACKGROUND: Type 2 diabetes mellitus (T2DM) requires sustained glycemic control to prevent long-term complications. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective therapies, traditionally administered via injection. The introduction of oral formulations, such as oral semaglutide, may improve patient adherence and persistence. METHODS: A systematic review with descriptive pooled synthesis was conducted using studies identified from PubMed, ClinicalTrials.gov, and relevant real-world observational data sources. Adherence and persistence outcomes were summarized and compared…

Protecting Musculoskeletal Development and Physical Function in Adolescents on GLP-1 Therapy.

Glucagon-like peptide-1 receptor agonists (GLP-1s), including semaglutide and liraglutide, are effective pharmacologic options for pediatric obesity, producing significant weight loss, cardiometabolic improvements, and reductions in barriers to physical activity. By alleviating pain, mechanical load, and psychosocial burden, these agents can also create a window to initiate sustainable health behaviors in adolescents. However, use during critical developmental periods raises concerns regarding long-term effects on musculoskeletal maturation. Adolescence is marked by rapid accrual of muscle and…

Evolution of incretin-based therapies: From GLP-1 monotherapy to dual and triple agonists: A new era in metabolic therapy.

Incretin-based therapies have revolutionised the management of metabolic disorders, transitioning from DPP-4 inhibitors to advanced GLP-1 re … d evidence. While DPP-4 inhibitors offer modest glycaemic benefits, GLP1RAs such as liraglutide and semaglutide have demonstrated significant weight loss and cardiometabolic protection. Dual GIP/GLP-1 agonist tirzepatide and triple agonist retatrutide have shown unprecedented efficacy, with up to 24% body weight reduction and improvement in hepatic and inflam …

Trends in utilization of glucagon-like peptide‑1 receptor agonists, sodium-glucose cotransporter‑2 inhibitors, and metabolic bariatric surgery in U.S. adults with diabetes and obesity.

AIMS: To characterize trends in utilization of glucagon-like peptide‑1 receptor agonists (GLP‑1RAs), sodium-glucose cotransporter‑2 inhibito … edication classes increased over time (GLP-1RAs: 1,988 to 44,852; SGLT2is: 861 to 19,892). In 2024, semaglutide (62.2%) and tirzepatide (32.6%) were the most initiated GLP-1RAs; MBS was rare (0.7% of treatments). Median treatment duration was 240 days for GLP‑1RAs and 254 days for SGLT2is; ∼50% were adherent. Tirzepatide had the highest adherence and persiste …

A Novel Microfluidic Strategy for the Fabrication of α-Lactalbumin Nanomicelles Paves a New Path for Antiobesity Technology.

Obesity, a global chronic metabolic disorder, poses a major risk for multiple comorbidities. Sulforaphene (SE) exerts antiobesity effects bu … t diet (HFD)-induced obese mice showed that M(α-Lac-SE) produced stronger fat-reducing effects than semaglutide under the present experimental conditions, while inducing markedly lower kaolin intake-associated pica behavior, a surrogate indicator of nausea-like gastrointestinal discomfort. In vitro, M(α-Lac-SE) entered adipocytes via caveolin/lipid raft-media …

The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus.

Metabolic dysfunction-associated steatohepatitis (MASH), a potentially progressive form of metabolic dysfunction-associated steatotic liver disease (MASLD), increases risk of fibrosis progression, cirrhosis, and liver-related and cardiometabolic morbidity. The first licensed pharmacotherapies, resmetirom and semaglutide, mark a shift in management but practical guidance for real-world implementation is lacking. The British Association for the Study of the Liver and British Society of Gastroenterology MASLD special interest group developed consensus recommendations on patient selection, lifesty…

GLP-1 Receptor Agonists as Molecular Relievers of Lipotoxic Stress: From Pancreatic Beta-Cell Cholesterol Efflux to Systemic and Tissue-Specific Metabolic Protection.

GLP-1RAs improve glycemia and body weight, but their effects extend beyond insulin secretion and appetite suppression. Experimental evidence … that pericentral liver sinusoidal endothelial GLP-1 receptors contribute to weight-loss-independent semaglutide-mediated improvements in steatosis, fibrosis and immune remodeling; whether an analogous causal mechanism operates in human MASH remains unknown. This review integrates systemic nutrient unloading, beta-cell cholesterol homeostasis and intrahepatic …

GLP-1 Receptor Agonists and Tirzepatide in Men Seeking Fertility: A Structured Narrative Review and Proposed Clinical Framework.

Glucagon-like peptide-1 (GLP-1) receptor agonists and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide are increasingly used to treat obesity and type 2 diabetes in men of reproductive age, but practical guidance for counseling men planning fatherhood remains limited. This structured narrative review distinguishes endocrine, semen, sexual-function, and clinical fertility outcomes. In metabolically impaired men, studies largely involving liraglutide or semaglutide report increases in total testosterone; free-testosterone findings are inconsistent, a…

Многоцелевые лекарственные препараты: новые 2025 и послерыночного контроля за безопасностью наркотиков, 2022-2024.

Полифармакология предназначена для развития соединений, действующих по крайней мере на two целевые показатели (многоцелевые лиганды, МТДЛ). В 2025, Европейское агентство по медицине (ЕМА), 38 наркотиков, и 11 из них были MTDL. Большинство из них - антитела-наркотики, биконкретные антитела или ингибиторы киназы, все из которых указаны для лечения опухолей, включая датопотамаб дерукстекан (гормон-позитивный рецептор, HER2-negative Рак молочной железы), тизотумаб ведотин (сокращенная шейная карцинома), линвосельтамб (четвёртая линия лечения множественной миеломы) и эрдафитиниб (сокращенная уротел

Совпадение в аннотации оригинала
Polypharmacology is dedicated to the development of compounds acting on at least two targets (multi-target-directed ligands, MTDLs). In 2025 … e-1 and glucose-dependent insulinotropic polypeptide analogue) compared to the single-targeted drug semaglutide (glucagon-like peptide-1 analogue), including lower reporting rates of acute kidney injury and no significant suicidality signal.

Weight Loss as a Determinant of Histological Improvement in Metabolic Dysfunction-Associated Steatotic Liver Disease in People With Obesity. A Systematic Review and Network Meta-Analysis of Randomised Clinical Trials.

BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to obesity and insulin resistance, and sustai … (TBWL%) and histologic outcomes. RESULTS: Six RCTs (n = 1379) met inclusion criteria. Tirzepatide, semaglutide, sleeve gastrectomy and Roux-en-Y gastric bypass were superior to placebo or standard care for achieving MASH resolution. Because the network was weakly connected and largely placebo-anchored, indirect estimates were imprecise. Across study arms, gr …

Weight Management Strategies to Reduce Metabolic Morbidity in Women With Polycystic Ovary Syndrome.

PURPOSE OF REVIEW: Polycystic Ovary Syndrome (PCOS) affects 10-15% of women of reproductive age and is associated with a heightened risk of … improvements in metabolic markers like blood pressure and glycemic control. GLP-1 RAs, particularly semaglutide, similarly deliver significant weight loss (10-15% over 1-2 years) and metabolic benefits. While there is limited data specifically targeting PCOS, emerging studies suggest GLP-1 RAs can improve weight, insulin sensitivity, and menstrual regularity …

Major Adverse Cardiovascular Event Outcomes in Patients With Obesity and Type 2 Diabetes Undergoing Medical Weight Management.

OBJECTIVE: We assessed the impact of medical weight management (MWM; lifestyle modification ± obesity medications) on major adverse cardiova … dings must be validated in future studies, given that more effective weight loss medications (e.g., semaglutide, tirzepatide) were not available.

GLP-1 receptor agonists in Alzheimer's and Parkinson's disease: endocrine pathways, clinical evidence, and future directions.

Initially developed for type 2 diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are now emerging as promising cand … nitive test will come from large, ongoing phase 3 programs, such as the EVOKE and EVOKE+ trials for semaglutide. Should these trials are successful, GLP-1RAs could become a cornerstone of earlier, mechanism-based intervention strategies for neurodegenerative diseases.

GLP1 and GIP Receptor Agonists: Effects on the Gastrointestinal Tract and Management Strategies for Primary Care Physicians.

Type 2 diabetes and obesity drive significant morbidity, mortality, and health care costs in the United States. Clinicians increasingly pres … of retained gastric contents but not with increased aspiration risk. Long-acting formulations (eg, semaglutide, dulaglutide, and tirzepatide, among others), high doses, procedures during dose escalation, and gastrointestinal comorbidities that delay gastric emptying raise risk of retained gastric contents. In most cases, clinicians can continue GLP1-RAs peri …

GLP-1 receptor agonist use during immune checkpoint inhibitor therapy is associated with mortality and Immune-Related adverse events across cancer types in People with type 2 Diabetes: A Target-Trial emulation.

AIMS: To evaluate whether Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use at immune checkpoint inhibitor (ICI) start is associated w … nd composite immune-related adverse events (irAEs). Prespecified per-protocol, 90-day landmark, and semaglutide-only analyses assessed robustness. RESULTS: GLP-1 RA co-exposure was associated with lower mortality (hazard ratio [HR] 0.55, 95 % CI 0.51-0.61; 36-month absolute risk difference [ARD] - 16.41 %; number needed to treat [NNT] 5). Hospitalization (HR …

Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review.

Alopecia has recently been reported as a potential emerging adverse effect associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs), which are widely prescribed for weight loss. While gastrointestinal symptoms remain the most frequently documented adverse effects, an increasing number of reports describe hair loss events in patients treated with semaglutide, liraglutide, tirzepatide, and dulaglutide. This scoping review aimed to synthesize the available evidence regarding this potential association. A systematic literature search was conducted across PubMed, Scopus, Google Scholar,…

Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice.

Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent progressive liver disease. Currently, there is only one drug for NAFLD treatment, and the options are limited. Phosphodiesterase-4 (PDE-4) inhibitors have potential in treating NAFLD. Therefore, this study aims to investigate the effect of roflumilast on NAFLD. Here, we fed ob/ob mice to induce the NAFLD model by GAN diet. Roflumilast (1 mg/kg) was administered orally once daily. Semaglutide (20 nmol/kg), used as a positive control, was injected subcutaneously once daily. Our findings showed that roflumilast has beneficial effects…

Long-Term Effects of Incretin-Based Drugs on Glycemic Control in Permanent Neonatal Diabetes.

Permanent neonatal diabetes mellitus (PNDM) is a genetic disorder, characterized by a decrease in endogenous insulin secretion. Therefore, e … uble dosing of sitagliptin and subsequent switching to the glucagon-like peptide-1 receptor agonist semaglutide (0.25 mg/week followed by 0.5 mg/week) further decreased hemoglobin A1c values, with graded improvements in endogenous insulin secretion. There were no episodes of hypoglycemia during which glibenclamide was titrated down from 0.6 to 0.4 mg/kg/day. …